| Filed On | Filing |
|---|---|
| 29 Jul 2025 |
8-K/A: Other Events
LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – |
| 23 May 2023 |
8-K/A: Financial Statements and Exhibits
On May 17, 2023 (the “Closing Date”), EyePoint Pharmaceuticals, Inc. (the “Company”) entered into a product rights agreement (the “Product Rights Agreement”) with Alimera Sciences, Inc. (“Alimera”) to grant to Alimera an exclusive (even ... |
| 12 Jan 2022 |
8-K/A: Other Events
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation January 2022 Exhibit 99.1 |
| 16 Jan 2020 |
8-K/A: Other Events
INVESTOR PRESENTATION JANUARY 2020 NASDAQ: EYPT Exhibit 99.1 |
| 09 Sep 2019 |
8-K/A: Submission of Matters to a Vote of Security Holders
The Company has determined, in light of and consistent with the advisory vote of the Company’s stockholders as to the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, to inc... |
| 11 Jun 2018 |
8-K/A: Completion of Acquisition or Disposition of Assets; Other Events
We have audited the accompanying financial statements of Icon Bioscience, Inc. (the Company), which comprise the balance sheets as of December 31, 2017 and 2016, and the related statements of operations, stockholders’ equity (deficit) an... |
Loading...